Latest news with #ZYXI
Associated Press
18-05-2025
- Business
- Associated Press
ZYXI DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - May 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the 'Class Period'), of the important May 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zynex class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, Defendants failed to disclose to investors that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, Zynex inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants' positive statements about the Zynex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zynex class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Associated Press
17-05-2025
- Business
- Associated Press
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zynex
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Zynex between March 13, 2023 and March 11, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - May 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ('Zynex' or the 'Company') (NASDAQ: ZYXI) and reminds investors of the May 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that Zynex shipped products, including electrodes, in excess of need; (2) that, as a result of this practice, the Company inflated its revenue; (3) that the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) that, as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. On June 4, 2024, medical journal STAT published a report on Zynex entitled 'How a device maker inundated pain patients with unwanted batteries and surprise bills.' The report claimed Zynex engaged in an 'oversupplying scheme' by sending inordinate amounts of monthly supplies like electrode pads and batteries in order to 'bill insurers for thousands of dollars more than it otherwise could.' The report further revealed that, as a result of this practice, insurers were 'kicking the company out of network.' On this news, Zynex's stock price fell $0.50 per share, or 5%, to close at $9.35 per share on June 4, 2024, on unusually heavy trading volume. On March 11, 2025, after the market closed, Zynex reported its fourth quarter and full year 2024 financial results, revealing a significant revenue 'shortfall' in the quarter 'due to slower than normal payments from certain payers.' Zynex further revealed 'Tricare has temporarily suspended payments as they review prior claims.' Tricare is the health insurance program for the U.S. military. On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025, on unusually heavy trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Zynex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Zynex, Inc. class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit
Associated Press
14-05-2025
- Business
- Associated Press
ZYXI DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Zynex, Inc. Investors to Secure Counsel Before Important May 19 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - May 13, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the 'Class Period'), of the important May 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zynex class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, Defendants failed to disclose to investors that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, Zynex inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants' positive statements about the Zynex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zynex class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Associated Press
11-05-2025
- Business
- Associated Press
ZYXI DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 19 Deadline in Securities Class Action
New York, New York--(Newsfile Corp. - May 11, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the 'Class Period'), of the important May 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Zynex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Zynex class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, Defendants failed to disclose to investors that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, Zynex inflated its revenue; (3) Zynex's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) as a result of the foregoing, defendants' positive statements about the Zynex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Zynex class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] To view the source version of this press release, please visit
Yahoo
12-03-2025
- Business
- Yahoo
Zynex Inc (ZYXI) Q4 2024 Earnings Call Highlights: Navigating Challenges and Opportunities
Net Revenue: $46 million in Q4 2024, compared to $47.3 million in Q4 2023. Device Revenue: $14.8 million in Q4 2024, down from $16.3 million in Q4 2023. Supplies Revenue: $31.2 million in Q4 2024, up from $31 million in Q4 2023. Gross Profit: $36 million or 78% of revenue in Q4 2024, compared to $37 million or 78% in Q4 2023. Sales and Marketing Expenses: $19.3 million in Q4 2024, down from $21.7 million in Q4 2023. G&A Expenses: $17.3 million in Q4 2024, up from $13 million in Q4 2023. Net Loss: $615,000 or $0.02 per share in Q4 2024, compared to net income of $1.2 million or $0.04 per share in Q4 2023. Adjusted EBITDA: $584,000 in Q4 2024, compared to $9.9 million in Q4 2023. Cash Flows from Operations: $2.4 million in Q4 2024 and $12.7 million for the full year. Cash Balance: $39.6 million at the end of Q4 2024, up 5% from Q3's balance of $37.6 million. Working Capital: $58.3 million as of December 31, 2024. Sales Force: Reduced from approximately 475 to 330 people by the end of 2024. Revenue per Sales Rep: Increased 22% to $490,000 on average in 2024. Projected Q1 2025 Revenue: Approximately $30 million. Projected Q1 2025 Net Loss: Between $9 million and $10 million. Warning! GuruFocus has detected 4 Warning Signs with ZYXI. Release Date: March 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Zynex Inc (NASDAQ:ZYXI) reported a 4% increase in revenue for 2024, with order growth of 16% for the year. The company has diversified its revenue streams by adding new products, including internally developed and private label products. Positive test results for the NiCO pulse oximeter were received from trials at Duke University and the University of California, San Francisco. Zynex Inc (NASDAQ:ZYXI) has restructured its sales force, resulting in a 22% increase in revenue per sales representative. The company has a strong cash position with $39.6 million on the balance sheet, up 5% from the previous quarter. TRICARE has temporarily suspended payments to Zynex Inc (NASDAQ:ZYXI), affecting 20% to 25% of the company's revenue. The company reported a net loss of $615,000 in Q4 2024 compared to a net income of $1.2 million in Q4 2023. Adjusted EBITDA for Q4 2024 was significantly lower at $584,000 compared to $9.9 million in Q4 2023. The FDA submission for the NiCO pulse oximeter has been delayed into 2025, impacting potential revenue generation. Zynex Inc (NASDAQ:ZYXI) has reduced its workforce by 15%, primarily affecting corporate office employees, to manage costs amid revenue uncertainties. Q: Could you give us a sense of what was accomplished in the fourth quarter regarding the 15% staff reduction and how it will affect your OpEx lines? A: Daniel Moorhead, CFO, explained that less than half of the $30 million-plus in annual savings was achieved during 2024, with the rest implemented in Q1 2025. Sales expenses are expected to decrease by $1-2 million, and G&A expenses will also see a similar reduction. Q: Could you elaborate on the commercial path to market for the NiCO pulse oximeter? A: Donald Gregg, President of Zynex Monitoring Solutions, stated that they are considering multiple strategies, including direct sales, partnerships, and indirect sales through 1099 organizations. They are prepared to execute these plans upon FDA clearance. Q: What was the nature of the 2022 audit by TRICARE related to billing practices, and why didn't you have visibility into TRICARE's actions? A: Anna Lucsok, COO, mentioned that the audit was a routine post-payment audit with standard adjustments. The lack of visibility into TRICARE's recent actions is due to unclear communication from TRICARE regarding specific issues. Q: Why don't you have visibility into sales for 2025, given that 75% of your business is still being reimbursed? A: Thomas Sandgaard, CEO, explained that the uncertainty with TRICARE, which represents a significant portion of revenue, makes it difficult to provide guidance. They are confident in resolving the issue but are taking a conservative approach until more clarity is obtained. Q: What is your plan for the April meeting with TRICARE, and have they requested specific information? A: Anna Lucsok, COO, stated that TRICARE has provided vague guidance, but Zynex plans to present data on compliance with policies and refer to the 2022 audit findings. They aim to clarify and resolve the issues during the meeting. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
